Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandem autologous stem cell transplantation plus anti-GD2 antibody therapy for high-risk neuroblastoma
jRCTs031250042Recruiting
- Start
- May 2025
- Countries
- 1
01
Overview
Open-label, single-arm trial in neuroblastoma. Primary endpoint: Three-year progression-free survival. Started May 2025; status: recruiting.
02
Conditions
neuroblastoma
Beyond the preview
Go deeper on jRCTs031250042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250042.